Condition Directory

ALS clinical trials

Directory of U.S. ClinicalTrials.gov public records for ALS. Browse ALS recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 22, 2026 Report an issue

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Current sort

How ALS studies are organized in the registry

Listings appear under both the abbreviation ALS and the full name “amyotrophic lateral sclerosis,” and some related records use “motor neuron disease.” The total volume is modest, so browsing the unfiltered list is practical; expanded-access records also appear in this condition and are labeled as such in the study-type field.

Terms that often appear in related listings

amyotrophic lateral sclerosis motor neuron disease SOD1 expanded access

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 20 matching trials for ALS.

Live ClinicalTrials.gov results.

Active filters: "SOD1" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Amyotrophic Lateral Sclerosis
Interventions: INS1202; Genetic
Lead sponsor: Insmed Gene Therapy LLC; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: La Jolla, California • Palo Alto, California • Columbia, Missouri + 2 more

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Tofersen; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Tofersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Interventions: Tofersen, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2037
U.S. locations: 1
States / cities: Miami, Florida

Conditions: ALS
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 105 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AMT-162; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 8 more

Conditions: ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Interventions: Tofersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 16
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 13 more

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease, Lou Gehrigs Disease, Familial Disease, Amyotrophic Lateral Sclerosis, Sporadic, Muscular Dystrophy, Miyoshi Myopathy, Amyotrophic Lateral Sclerosis With Dementia
Interventions: Not listed
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis, Familial, Amyotrophic Lateral Sclerosis, Sporadic
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
Interventions: Tofersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
U.S. locations: 19
States / cities: Anchorage, Alaska • Los Angeles, California • Orange, California + 16 more

Conditions: Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Familial Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Motor Neuron Disease, Familial
Interventions: Rehabilitation; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

About this ALS clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list ALS as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within ALS.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

ALS clinical trials

How ALS studies are organized in the registry

Filter and sort this condition

Live official records

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Tofersen in Non-SOD1 ALS

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study

Amyotrophic Lateral Sclerosis (ALS) Families Project

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Long-Term Evaluation of BIIB067 (Tofersen)

Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

SOD1 Kinetics Measurements in ALS Patients

Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

Rehabilitation in SOD1 ALS Treated With Tofersen

About this ALS clinical trials directory page